Loop diuretics in acute decompensated heart failure necessary? Evil? A necessary evil?

Circulation: Heart Failure

Volumn 2, Issue 1, 2009, Pages 56-62

  Felker, G Michael ^a,c   O'Connor, Christopher M ^a   Braunwald, Eugene ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Diuretics; Heart failure; Trials

Indexed keywords

FUROSEMIDE; LOOP DIURETIC AGENT;

CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VISUAL ANALOG SCALE;

ACUTE DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; RISK FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME;

EID: 70449491019     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.108.821785     Document Type: Review

References (49)

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Members of the Statistics C, Stroke Statistics S, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. Heart Disease and Stroke Statistics-2006 Update: a Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006; 113:e85- e151.
2. Felker GM, Adams KF, Konstam MA, O'Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J. 2003; 145:S18 -S25.
3. Felker GM, Leimberger JD, Califf RM, Cuffe MS, Massie BM, Adams KF Jr, Gheorghiade M, O'Connor CM. Risk stratification after hospitalization for decompensated heart failure. J Card Fail. 2004; 10:460-466.
4. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA: J Am Med Assoc. 2003; 290: 2581-2587.
5. Ramirez A, Abelmann WH. Cardiac decompensation. New Eng J Med. 1974; 290:499 -501.
6. Lee DS, Mamdani MM, Austin PC, Gong Y, Liu PP, Rouleau JL, Tu JV. Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. AmJ Med. 2004; 116:581-589.
7. Emerman CL, Marco TD, Costanzo MR, Peacock WF; for the ASAC. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE(R) Registry. J Card Fail. 2004; 10:S116 -S117.
8. Adams Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100, 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005; 149:209 -216.
9. Adams KF, Lindenfeld J, Arnold JM, Baker D, Barnhard DH, Baughman KL, Boehmer JP, Deedwania P, Dunbar SB, Elkayam U, Gheorghiade M, Howlett J, Konstam MA, Kronenberg MW, Massie BM, Mehra MR, Miller AB, Moser DK, Patterson JK, Rodeheffer RJ, Sackner-Bernstein JD, Silver MA, Starling MR, Stevenson LW, Wagoner LE. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006; 12: 1-119.
10. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112:1825-1852.
11. Shah MR, Stevenson LW. Searching for evidence: refractory questions in advanced heart failure. J Card Fail. 2004; 10:210 -218.
12. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudintoretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left-ventricular dysfunction with and without congestive-heart- failure - a substudy of the studies of left-ventricular dysfunction (SOLVD). Circulation. 1990; 82:1724 -1729.
13. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart-failure - activation of the neurohumoral axis. Ann Intern Med. 1985; 103:1- 6.
14. Bayliss J, Norell M, Canepaanson R, Sutton G, Poolewilson P. Untreated Heart-failure - clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987; 57:17-22.
15. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001; 96:132-143.
16. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT. BG9719 (CVT-124), an A(1) adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002; 105:1348 -1353.
17. Mullens W, Abrahams Z, Skouri HN, Francis GS, Taylor DO, Starling RC, Paganini E, Tang WHW. Elevated intra-abdominal pressure in acute decompensated heart failure. J Am Coll Cardiol. 2008; 51:300 -306.
18. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, Felker GM, Adams KF Jr, Califf RM, Gheorghiade M; for the O-CHFI. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) Study. Circulation. 2005; 111:2454 -2460.
19. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999; 100:1311-1315.
20. McCurley JM, Hanlon SU, Wei Sk, Wedam EF, Michalski M, Haigney MC. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol. 2004; 44:1301-1307.
21. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006; 27:1431-1439.
22. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Wang Y. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004; 147:331-338. (Pubitemid 38176835)
23. Hasselblad V, Stough WG, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, Adams KF Jr. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE Trial. Eur J Heart Fail. 2007; 9:1064 -1069.
24. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006; 97:1759 -1764.
25. Neuberg GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002; 144:31-38.
26. Philbin EF, Cotto M, Rocco TA Jr, Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. Am J Cardiol. 1997; 80:519 -522.
27. Mielniczuk LM, Tsang SW, Desai AS, Nohria A, Lewis EF, Fang JC, Baughman KL, Stevenson LW, Givertz MM. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail. 2008; 14:388 -393.
28. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004; 43:61- 67. (Pubitemid 38045917)
29. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA. 2007; 298:2009 -2019.
30. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan I. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA: J Am Med Assoc. 2007; 297: 1332-1343.
31. Salvator DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2005:3.
32. Gerlag PG, van Meijel JJ. High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med. 1988; 148:286 -291.
33. Wilcox CS, Mitch WE, Kelly RA, Skorecki K, Meyer TW, Friedman PA, Souney PF. Response of the kidney to furosemide. 1. Effects of salt intake and renal compensation. J Lab Clin Med. 1983; 102:450-458.
34. Kaissling B, Bachmann S, Kriz W. Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. Am J Physiol. 1985; 248:F374 -F381.
35. Stevenson LW, Nohria A, Mielniczuk L. Torrent or torment from the tubules? Challenge of the cardiorenal connections. J Am Coll Cardiol. 2005; 45:2004 -2007.
36. Vanmeyel JJM, Smits P, Dormans T, Gerlag PGG, Russel PGM, Gribnau PWJ. Continuous-infusion of furosemide in the treatment of patients with congestive-heart-failure and diuretic resistance. J Int Med. 1994; 235: 329-334.
37. Vanmeyel JJM, Smits P, Russel FGM, Gerlag PGG, Tan Y, Gribnau FWJ. Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy-volunteers. Clin Pharmacol Ther. 1992; 51:440-444.
38. Rudy DW, Voelker JR, Greene PK, Esparza FA, Brater DC. Loop diuretics for chronic renal-insufficiency - a continuous infusion is more efficacious than bolus therapy. Ann Intern Med. 1991; 115:360 -366.
39. Magovern JA, Magovern GJ. Diuresis in hemodynamically compromised patients - continuous furosemide infusion. Ann Thorac Surg. 1990; 50: 482-484.
40. Copeland JG, Campbell DW, Plachetka JR, Salomon NW, Larson DF. Diuresis with continuous infusion of furosemide after cardiac-surgery. Am J Surg. 1983; 146:796 -799.
41. Lawson DH, Gray JMB, Henry DA, Tilstone WJ. Continuous infusion of frusemide in refractory edema. BMJ. 1978; 2:476-476.
42. Aaser E, Gullestad L, Tollofsrud S, Lundberg J, Hall C, Djoseland O, Kjekshus J, Forfang K. Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure. Scandinavian J Clin Lab Invest. 1997; 57:361-367.
43. Pivac N, Rumboldt Z, Sardelic S, Bagatin J, Polic S, Ljutic D, Naranca M, Capkun V. Diuretic effects of furosemide infusion versus bolus injection
44. Dormans TPJ, Vanmeyel JJM, Gerlag PGG, Tan Y, Russel FGM, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996; 28: 376-382.
45. Kramer WG, Smith WB, Ferguson J, Serpas T, Grant AG, Black PK, Brater DC. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure. J Clin Pharmacol. 1996; 36:265-270.
46. Lahav M, Regev A, Raanani P, Theodor E. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive-heart-failure. Chest. 1992; 102:725-731.
47. Schuller D, Lynch JP, Fine D. Protocol-guided diuretic management: comparison of furosemide by continuous infusion and intermittent bolus. Crit Care Med. 1997; 25:1969 -1975.
48. Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, Argano C, Tuttolomondo A, Paterna S. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003; 145:459-466.
49. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham O, Marghitay D, Koren M, Blatt A, Moshkovitz Y, Zaidenstein R, Golik A. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998; 351: 389-393.